Tissium raises €30M in equity, €30M in debt

In emerging news, medtech Tissium raises €30M in equity, €30M in debt The funds will be used to roll out its tech in the US. Medtech Tissium raises €30M in equity, €30M in debt The funds will be used to roll out its tech in the US.John Reynolds 40 minutes ago Share Facebook Twitter Linkedin Share Send email Copy link A French startup which uses a novel technology to reconstruct damaged tissue and restore it to its natural state has raised €30m in equity and taken out up to €30m in debt financing, it said today.Tissium has developed materials called ”biomorphic programmable polymers” that act as an adhesive, which bind nerves together inside tissue, circumventing the need for invasive stitches.Key players s technology is used to repair heart defects, hernias, and damaged nerves. Two of its products- one for nerve repair, one for hernia treatment- have received approval by the US Food and Drug Administration (FDA). Market ImplicationsForward-Looking IndicatorsContinued consolidation expected in the sectorIncreasing focus on digital transformation and innovationGrowing importance of ESG considerations Expert CommentaryChristophe Bancel, CEO and co-founder, Tissium, We are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform." TISSIUM medtech Frnace Write Comment Tissium raises €30M in equity, €30M in debt Comments Would you like to write the first comment? Looking AheadFor complete details on this development, refer to the original report from Tech.eu. Frequently Asked Questions